This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

The results of numerous high-impact Phase III clinical trials that could affect kidney-related medical care were presented in person at American Society of Nephrology Kidney Week 2026, Oct. 22–25.

Atacicept inhibits the cytokines B-cell activating factor (BAFF, also known as B-lymphocyte stimulator, or BLyS) and a proliferation-inducing ligand (APRIL) involved in the pathogenesis of IgA nephropathy. In the interim analysis of the Phase III ORIGIN 3 trial, atacicept achieved a statistically significant reduction in urinary protein-to-creatinine ratio at week 36.

Following FDA review, atacicept received accelerated approval. In the latest analysis of ORIGIN 3 through two years, atacicept demonstrated additional benefits for patients.

"ORIGIN 3 stands as a landmark trial in kidney medicine, demonstrating kidney protection with atacicept through stabilization of eGFR and a marked reduction in the risk of kidney disease progression. The safety profile was comparable to placebo, with no evidence of increased infection risk," said corresponding author Jonathan Barratt, MBChB, Ph.D., FRCP, of the University of Leicester.

"Together with a small-volume, self-administered autoinjector, these findings represent an important advance for patients with IgA nephropathy."

Sibeprenlimab targets the cytokine a proliferation-inducing ligand (APRIL), one of the immune-related drivers of IgA nephropathy, a condition that affects patients often at a young age and places them at a significant lifetime risk of kidney failure. In the Phase III VISIONARY trial, sibeprenlimab reduced the risk of serious kidney function loss or kidney failure in adults with IgA nephropathy by 97% compared with placebo, with kidney function remaining stable over two years.

Source link